Intravitreal bevacizumab for peripapillary choroidal neovascular membranes

Arch Ophthalmol. 2012 Aug;130(8):1073-5. doi: 10.1001/archophthalmol.2012.465.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Bevacizumab
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Macular Degeneration / diagnosis
  • Macular Degeneration / drug therapy
  • Male
  • Middle Aged
  • Retreatment
  • Subretinal Fluid
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab